New drug development project
Dry-eye syndrome treatment: All dry-eye syndrome medicine in the market are all eye-drop types that are uncomfortable to use. In order to address such weaknesses, the first-ever oral administration dry-eye syndrome medicine SA-001 was successfully created by transforming the eye-drop type to tablet types. It is currently in the second-phase clinical trials. There are no competing products in Korea or abroad, making it a one-of-a-kind drug.
The global dry-eye syndrome market is estimated to be around 2-3 billion won, but it is expected that once the oral administration medicine is launched, the market will be worth more than 5 trillion won.
We were the first in the world to develop the technologies for making orally consumed dry-eye syndrome medicine.